May 7, 2020 / 11:53 AM / 20 days ago

BRIEF-Moderna Says Phase 2 Study Of Its Coronavirus Vaccine Candidate Expected To Begin Shortly

May 7 (Reuters) - Moderna Inc:

* MODERNA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

* Q1 REVENUE ESTIMATE $17.1 MILLION — REFINITIV IBES DATA

* FINALIZING PROTOCOL FOR PHASE 3 STUDY OF CORONAVIRUS VACCINE MRNA-1273, EXPECTED TO BEGIN IN EARLY SUMMER OF 2020

* GIVEN CURRENT STRATEGIC PRIORITIES, FABRY DISEASE PROGRAM (MRNA-3630) IS BEING DISCONTINUED

* DUE TO COVID-19, ENROLLMENT AND NEW SITE INITIATION PAUSED FOR METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA CLINICAL TRIALS

* A 600 PARTICIPANT PHASE 2 STUDY IS EXPECTED TO BEGIN SHORTLY FOR ITS CORONAVIRUS VACCINE CANDIDATE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below